You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SGN-35 (BRENTUXIMAB VEDOTIN)

Showing 1 - 25 of 3,066
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,

Recruiting
  • Recurrent Hodgkin Lymphoma
  • +3 more
  • Brentuximab Vedotin
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 4, 2022

Hodgkin Lymphoma Trial in New York (Mocetinostat Plus Brentuximab Vedotin)

Completed
Has Results
  • Hodgkin Lymphoma
  • Mocetinostat Plus Brentuximab Vedotin
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 10, 2022

HIV Infection, HIV-associated Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma Trial in France (brentuximab vedotin,

Active, not recruiting
  • HIV Infection
  • +3 more
  • brentuximab vedotin
  • +3 more
  • Clamart, France
  • +5 more
Aug 11, 2022

Recurrent Classic Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Nivolumab)

Recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Brentuximab Vedotin
  • Nivolumab
  • Duarte, California
    City of Hope Medical Center
Feb 16, 2022

T-Cell Lymphoma Trial (Brentuximab vedotin)

Not yet recruiting
  • T-Cell Lymphoma
  • Brentuximab vedotin
  • (no location specified)
Jun 30, 2022

Hodgkin Lymphoma Trial in Houston (Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab)

Not yet recruiting
  • Hodgkin Lymphoma
  • Brentuximab vedotin
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 20, 2023

Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Cyclosporine, Pharmacokinetic

Active, not recruiting
  • Recurrent Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Brentuximab Vedotin
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Feb 17, 2022

CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma Trial in Houston (Brentuximab Vedotin, Laboratory Biomarker

Recruiting
  • CD30-Positive Neoplastic Cells Present
  • Malignant Mesothelioma
  • Brentuximab Vedotin
  • Laboratory Biomarker Analysis
  • Houston, Texas
    M D Anderson Cancer Center
Jan 3, 2022

Mycosis Fungoides Trial in Houston (Brentuximab vedotin)

Recruiting
  • Mycosis Fungoides
  • Brentuximab vedotin
  • Houston, Texas
    MD Anderson Cancer Center
Oct 14, 2022

Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Sacramento (Bendamustine Hydrochloride, Brentuximab

Recruiting
  • Recurrent Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Bendamustine Hydrochloride
  • Brentuximab Vedotin
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Dec 17, 2021

T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)

Withdrawn
  • T Cell Lymphoma
  • Brentuximab Vedotin
  • Kansas City, Kansas
    The University of Kansas Cancer Center, Westwood Campus
Feb 1, 2023

Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell

Recruiting
  • Recurrent Angioimmunoblastic T-Cell Lymphoma
  • +13 more
  • Brentuximab Vedotin
  • Pembrolizumab
  • Chicago, Illinois
    Northwestern University
Jun 15, 2022

Leukemia Trial in Houston (Brentuximab Vedotin, 5-Azacytidine)

Terminated
Has Results
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 7, 2022

Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in United States (drug, other,

Active, not recruiting
  • Classic Hodgkin Lymphoma
  • +2 more
  • Brentuximab Vedotin
  • +2 more
  • Duarte, California
  • +5 more
Mar 17, 2022

Diffuse Cutaneous Systemic Sclerosis Trial (Brentuximab vedotin)

Not yet recruiting
  • Diffuse Cutaneous Systemic Sclerosis
  • Brentuximab vedotin
  • (no location specified)
Apr 11, 2022

Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma Trial in United

Active, not recruiting
Has Results
  • Ann Arbor Stage IB Hodgkin Lymphoma
  • +10 more
  • Brentuximab Vedotin
  • Nivolumab
  • Palo Alto, California
  • +8 more
Jul 20, 2022

Diffuse Cutaneous Systemic Sclerosis Trial in London (Brentuximab Vedotin)

Recruiting
  • Diffuse Cutaneous Systemic Sclerosis
  • Brentuximab Vedotin
  • London, Ontario, Canada
    Rheumatology Clinic, St. Joseph's Health Care
Feb 3, 2022

Lymphatic Diseases Trial in Italy (Brentuximab Vedotin)

Completed
  • Lymphatic Diseases
  • Brentuximab Vedotin
  • Bologna, Italy
  • +3 more
Mar 21, 2022

Hodgkin Lymphoma, Adult Trial in United States (Brentuximab vedotin, ABVD)

Completed
Has Results
  • Hodgkin Lymphoma, Adult
  • Brentuximab vedotin
  • ABVD
  • Duarte, California
  • +5 more
Nov 8, 2021

AIDS-Related Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma Trial in France, United

Active, not recruiting
  • AIDS-Related Hodgkin Lymphoma
  • +11 more
  • Brentuximab Vedotin
  • +4 more
  • La Jolla, California
  • +27 more
Jul 27, 2022

Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma Trial in United States (brentuximab vedotin)

Terminated
  • Hodgkin Lymphoma
  • +2 more
  • brentuximab vedotin
  • Anaheim, California
  • +18 more
Dec 6, 2022

Lymphatic Diseases Trial in Italy (Brentuximab Vedotin, Bendamustine)

Terminated
  • Lymphatic Diseases
  • Bologna, BO, Italy
  • +4 more
May 26, 2021

Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large

Recruiting
  • Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma
  • +3 more
  • Brentuximab Vedotin
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 10, 2022

Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular

Recruiting
  • Ann Arbor Stage I Hodgkin Lymphoma
  • +13 more
  • Birmingham, Alabama
  • +16 more
Nov 23, 2021

Hodgkin Disease Trial in Belgium, France (Brentuximab Vedotin, Etoposide, Carboplatine)

Completed
  • Hodgkin Disease
  • Brentuximab Vedotin
  • +3 more
  • Bruxelles, Belgium
  • +18 more
Dec 6, 2021